Literature DB >> 2231001

Radioimmunoscintigraphy using iodine-131-anti-CEA monoclonal antibodies and thallium-201 scintigraphy in medullary thyroid carcinoma: a case report.

D E Zanin1, A van Dongen, C A Hoefnagel, P F Bruning.   

Abstract

This case report demonstrates the use of thallium-201 (201Tl) scans versus iodine-131- (131l) anti-CEA F(ab')2 scans in a patient with high serum CEA levels due to metastases of medullary thyroid carcinoma in the suprarenal region and sacroiliacal region. Scintigraphy using monoclonal antibodies directed against CEA showed a higher tumor uptake (0.26% dose and 0.64% dose, respectively) than a thallium scan and is believed to be promising for future radiotherapeutic applications.

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2231001

Source DB:  PubMed          Journal:  J Nucl Med        ISSN： 0161-5505            Impact factor:   10.057


  4 in total

Review 1.  Applications of monoclonal antibodies in the investigation, diagnosis, and treatment of retinoblastoma.

Authors:  J F Tarlton; D L Easty
Journal:  Br J Ophthalmol       Date:  1993-12       Impact factor: 4.638

2.  Potential role of fluorine-18-deoxyglucose (FDG) positron emission tomography (PET) in the staging of primitive and recurrent medullary thyroid carcinoma.

Authors:  P Gasparoni; D Rubello; G Ferlin
Journal:  J Endocrinol Invest       Date:  1997-10       Impact factor: 4.256

3.  Detection of cervical metastases of thyroid medullary carcinoma by MoAb anti-CEA scintigraphy and immunohistochemistry.

Authors:  S Parkkila; A Ahonen; P Torniainen; J Heikkilä; P Salmela
Journal:  Eur J Nucl Med       Date:  1995-09

4.  Pretargeted immunoscintigraphy in patients with medullary thyroid carcinoma.

Authors:  P Magnani; G Paganelli; C Songini; A Samuel; F Sudati; A G Siccardi; F Fazio
Journal:  Br J Cancer       Date:  1996-09       Impact factor: 7.640
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.